Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | SHBG | P04278 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761172 | 1.00 | CNR2 (0.36) | CNR2DPP4SHBGMEN1ALDH1A1 | |
| SCHEMBL1668635 | 1.00 | CNR2 (0.36) | CNR2DPP4SHBGMEN1ALDH1A1 | |
| SCHEMBL1668637 | 1.00 | CNR2 (0.36) | CNR2DPP4SHBGMEN1ALDH1A1 | |
| SCHEMBL30148076 | 1.00 | CNR2 (0.36) | CNR2DPP4SHBGMEN1ALDH1A1 | |
| SCHEMBL13320075 | 0.79 | CNR2 (0.35) | CNR2DPP4SHBG | |
| SCHEMBL24052391 | 0.77 | CNR2 (0.35) | CNR2DPP4SHBGMEN1ALDH1A1 | |
| SCHEMBL9360142 | 0.77 | CNR2 (0.35) | CNR2DPP4SHBG | |
| SCHEMBL253323 | 0.77 | CNR2 (0.35) | CNR2DPP4SHBG | |
| SCHEMBL7673902 | 0.77 | CNR2 (0.35) | CNR2DPP4SHBG | |
| SCHEMBL6507028 | 0.77 | CNR2 (0.35) | CNR2DPP4SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250157-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2007-07-31 | — | — | US | claimed |
| US-20060120976-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2006-06-08 | — | — | US | claimed |
| US-6955804-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DEMATICS (US) | 2005-10-18 | — | — | US | claimed |
| US-20040067209-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS | 2004-04-08 | — | — | US | claimed |
| US-6623724-B2 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2003-09-23 | — | — | US | claimed |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2002-10-03 | — | — | US | claimed |
| WO-2002051395-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES | CODON PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| WO-1998055085-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-12-10 | — | — | WO | claimed |
| US-7250157-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060120976-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS (US) | 2006-06-08 | — | — | US | disclosed |
| US-6955804-B2 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DEMATICS (US) | 2005-10-18 | — | — | US | disclosed |
| US-20040067209-A1 | Dermatological compositions and methods | APPLIED GENETICS INCORPORATED DERMATICS | 2004-04-08 | — | — | US | disclosed |
| US-6623724-B2 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2003-09-23 | — | — | US | disclosed |
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | APPLIED GENETICS INCORPORATED DERMATICS | 2002-10-03 | — | — | US | disclosed |
| WO-2002051395-A1 | TREATMENT OF NEURODEGENERATIVE DISEASES | CODON PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | disclosed |
| WO-1998055085-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | CODON PHARMACEUTICALS, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020141952-A1 | Regulating the melanin content of mammalian melanocytes by administering alcohols, diols, triols and their analogues | TYR, MITF, MC1R | CNR2 3791/4885DPP4 4520/4885SHBG 1150/4885 |
| US-20060120976-A1 | Dermatological compositions and methods | TYR, MITF, ALPG | CNR2 4006/4885DPP4 4119/4885SHBG 411/4885 |
| US-20040067209-A1 | Dermatological compositions and methods | TYR, MITF, ALPG | CNR2 4006/4885DPP4 4119/4885SHBG 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.